RxDoctor Payments Data

Alexander Chun, MD

Gastroenterology · New York, NYNPI 1770592685

Payments from drug & device makers

$17,839in general payments, 2019–2025

Across 940 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Gilead$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • QOL Medical, LLC$1K
  • Viiv Healthcare Company$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$795
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$17,09896%
  • Education$3222%
  • Other$4002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,839 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$196,380
Medicare patients
437
Services billed
1,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide14$817,299
RinvoqUpadacitinib15$94,651
BiktarvyBictegrav/Emtricit/Tenofov Ala16$61,457
DovatoDolutegravir Sodium/Lamivudine11$37,484
XifaxanRifaximin11$33,930
JardianceEmpagliflozin15$24,763
Mesalamine31$21,788
EliquisApixaban25$19,102
OzempicSemaglutide22$18,732
LinzessLinaclotide23$17,772
QuliptaAtogepant11$11,827
Mesalamine ErMesalamine41$7,329
ClenpiqSod Picosulf/Mag Ox/Citric Ac23$3,915
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates32$2,075
Esomeprazole Magnesium21$1,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$795$817,29914 claims
AbbVieRinvoq, Linzess, Qulipta$3,703$124,25149 claims
GileadBiktarvy$2,563$61,45716 claims
Viiv Healthcare CompanyDovato$1,078$37,48411 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,355$33,93011 claims
Boehringer IngelheimJardiance$107$24,76315 claims
PfizerEliquis$266$19,10225 claims
Novo NordiskOzempic$610$18,73222 claims
Ferring Pharmaceuticals Inc.Clenpiq$19$3,91523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →